C.Q. Pharmaceutical Holding Co., Ltd. (SHE:000950)
China flag China · Delayed Price · Currency is CNY
5.92
+0.05 (0.85%)
May 8, 2026, 3:04 PM CST

SHE:000950 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
82,26882,44780,25578,18567,65762,354
Other Revenue
--307.01212.62171.83166.87
82,26882,44780,56278,39767,82962,521
Revenue Growth (YoY)
0.88%2.34%2.76%15.58%8.49%38.26%
Cost of Revenue
76,41176,50774,64172,16262,03856,817
Gross Profit
5,8575,9405,9216,2355,7915,703
Selling, General & Admin
3,7883,8593,9673,6783,2983,078
Research & Development
0.760.470.320.383.2410.04
Other Operating Expenses
168.91168.06189.22212.55188.63155.73
Operating Expenses
3,9584,0274,6884,2793,6143,526
Operating Income
1,8991,9131,2321,9572,1772,177
Interest Expense
---1,138-1,340-1,123-1,106
Interest & Investment Income
464.47415.48488.19393.27355.29347.92
Currency Exchange Gain (Loss)
---0.170.180.44-0.1
Other Non Operating Income (Expenses)
-1,543-1,535-41.03-103.03-12.363.66
EBT Excluding Unusual Items
820.37793.47541.54906.961,3971,423
Impairment of Goodwill
---40.22-20.48-27.91-10.32
Gain (Loss) on Sale of Investments
-2.25-3.076.9216.162.32126.88
Gain (Loss) on Sale of Assets
4.634.6310.530.7910.053.52
Asset Writedown
-116.95-123.170.01-0.01-0.02-0.35
Other Unusual Items
--38.7362.9191.2537.35
Pretax Income
705.81671.86557.51966.331,4721,580
Income Tax Expense
158.62150.53155.72236.04309.5289.61
Earnings From Continuing Operations
547.19521.33401.79730.291,1631,291
Net Income to Company
547.19521.33401.79730.291,1631,291
Minority Interest in Earnings
-114.98-134.61-118.8-105.65-210.72-285.23
Net Income
432.21386.72282.99624.63952.281,005
Net Income to Common
432.21386.72282.99624.63952.281,005
Net Income Growth
41.58%36.65%-54.69%-34.41%-5.29%13.69%
Shares Outstanding (Basic)
1,7371,7581,7691,7351,7311,734
Shares Outstanding (Diluted)
1,7371,7581,7691,7351,7311,734
Shares Change (YoY)
-2.78%-0.62%1.94%0.21%-0.12%0.31%
EPS (Basic)
0.250.220.160.360.550.58
EPS (Diluted)
0.250.220.160.360.550.58
EPS Growth
45.63%37.50%-55.56%-34.54%-5.17%13.73%
Free Cash Flow
-716455.13-437.27264.1317.76-239.38
Free Cash Flow Per Share
-0.410.26-0.250.150.01-0.14
Dividend Per Share
--0.0600.0500.0600.105
Dividend Growth
--20.00%-16.67%-42.86%-
Gross Margin
7.12%7.21%7.35%7.95%8.54%9.12%
Operating Margin
2.31%2.32%1.53%2.50%3.21%3.48%
Profit Margin
0.53%0.47%0.35%0.80%1.40%1.61%
Free Cash Flow Margin
-0.87%0.55%-0.54%0.34%0.03%-0.38%
EBITDA
2,1822,1891,4792,2032,4082,346
EBITDA Margin
2.65%2.66%1.84%2.81%3.55%3.75%
D&A For EBITDA
282.95275.68246.6246.87231.17169.06
EBIT
1,8991,9131,2321,9572,1772,177
EBIT Margin
2.31%2.32%1.53%2.50%3.21%3.48%
Effective Tax Rate
22.47%22.41%27.93%24.43%21.02%18.33%
Revenue as Reported
--80,56278,39767,82962,521
Advertising Expenses
--9.429.5720.3923.49
Source: S&P Global Market Intelligence. Standard template. Financial Sources.